Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regen BioPharma (RGBPP) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Regen BioPharma (RGBPP) over the last 13 years, with Q3 2025 value amounting to -$572469.0.

  • Regen BioPharma's Profit After Tax fell 11143.98% to -$572469.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 million, marking a year-over-year decrease of 4597.7%. This contributed to the annual value of -$1.3 million for FY2025, which is 9072.09% down from last year.
  • Per Regen BioPharma's latest filing, its Profit After Tax stood at -$572469.0 for Q3 2025, which was down 11143.98% from -$167292.0 recorded in Q2 2025.
  • In the past 5 years, Regen BioPharma's Profit After Tax registered a high of $67.0 million during Q2 2022, and its lowest value of -$67.1 million during Q1 2022.
  • Its 5-year average for Profit After Tax is -$367323.2, with a median of -$130120.0 in 2024.
  • Over the last 5 years, Regen BioPharma's Profit After Tax had its largest YoY gain of 99407.33% in 2022, and its largest YoY loss of 1527054.91% in 2022.
  • Over the past 5 years, Regen BioPharma's Profit After Tax (Quarter) stood at $2.6 million in 2021, then tumbled by 38.16% to $1.6 million in 2022, then plummeted by 121.38% to -$349760.0 in 2023, then tumbled by 47.35% to -$515384.0 in 2024, then decreased by 11.08% to -$572469.0 in 2025.
  • Its Profit After Tax was -$572469.0 in Q3 2025, compared to -$167292.0 in Q2 2025 and -$19354.0 in Q1 2025.